| Brandon Everett Scott, FNP | |
|
420 Thomson Cir, Abbeville, SC 29620-5656 | |
| (864) 366-5011 | |
| Not Available |
| Full Name | Brandon Everett Scott |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Family |
| Location | 420 Thomson Cir, Abbeville, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245798727 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 222778 (South Carolina) | Primary |
| Entity Name | Abbeville County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649816216 PECOS PAC ID: 7719891506 Enrollment ID: O20031117000214 |
News Archive
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
This week, I answer questions from readers concerned about health insurance roadblocks in the face of a serious illness or medical crisis.
Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
› Verified 2 days ago
| Entity Name | Abbeville County Memorial Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063449361 PECOS PAC ID: 7719891506 Enrollment ID: O20080218000142 |
News Archive
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
This week, I answer questions from readers concerned about health insurance roadblocks in the face of a serious illness or medical crisis.
Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
› Verified 2 days ago
| Entity Name | Woodruff Road Urgent Care Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598073496 PECOS PAC ID: 7911182084 Enrollment ID: O20110505000224 |
News Archive
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
This week, I answer questions from readers concerned about health insurance roadblocks in the face of a serious illness or medical crisis.
Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
› Verified 2 days ago
| Entity Name | Edcare Consulting Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053534750 PECOS PAC ID: 5193086833 Enrollment ID: O20180221000847 |
News Archive
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
This week, I answer questions from readers concerned about health insurance roadblocks in the face of a serious illness or medical crisis.
Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandon Everett Scott, FNP Po Box 887, Abbeville, SC 29620-0887 Ph: (864) 366-5011 | Brandon Everett Scott, FNP 420 Thomson Cir, Abbeville, SC 29620-5656 Ph: (864) 366-5011 |
News Archive
XenoPort, Inc. announced today that it has initiated a Phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD) who remain symptomatic despite treatment with a proton pump inhibitor (PPI). The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
This week, I answer questions from readers concerned about health insurance roadblocks in the face of a serious illness or medical crisis.
Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders.
As the promise of using regenerative stem cell therapies draws closer, a consortium of biomedical scientists reports about 30 percent of induced pluripotent stem cells they analyzed from 10 research institutions were genetically unstable and not safe for clinical use.
› Verified 2 days ago
Patricia Siefferman, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 901 W Greenwood St, Suite 5, Abbeville, SC 29620 Phone: 864-366-9938 Fax: 864-366-0818 | |
Linda Lorraine Williams, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 W Greenwood St Suite 5, Abbeville, SC 29620 Phone: 864-366-9938 Fax: 864-366-0818 | |
Davis Renee Migdalas, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 W Greenwood St Ste 6, Abbeville, SC 29620 Phone: 864-366-9010 Fax: 864-366-9012 | |
Mrs. Katie Chandler Mumblow, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 601 Brooks St, Abbeville, SC 29620 Phone: 864-459-2121 | |
Mrs. Emily Horne Wallace, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 420 Thomson Cir, Abbeville, SC 29620 Phone: 864-366-5011 | |
Mrs. Jennifer Wright, ARNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 901 W Greenwood St Ste 1, Abbeville, SC 29620 Phone: 864-366-9681 Fax: 864-366-5600 |